Authors: Xuan Jiang Wei Guan Mengxia Li Wei Liang Yi Qing Nan Dai Shiheng Zhang Yi Deng Hao Meng Yuxin Yang Zhaoyang Zhong
Publish Date: 2014/09/11
Volume: 71, Issue: 2, Pages: 571-577
Abstract
This retrospective study was conducted to determine whether endostatin improves the efficacy and safety of platinumbased chemotherapy administered via both intravenous and arterial infusions for stage III/IV nonsmallcell lung cancer NSCLC Seventy one patients with confirmed pathological or cytological diagnosis of NSCLC from January 2008 to March 2013 were enrolled for the study Patients received three different therapeutic regimens until disease progression or an intolerable toxicity was evidenced Group C received chemotherapy administered by intravenous injection and subsequent radiotherapy Group IC received chemotherapy by intravenous injection and arterial infusion plus radiotherapy Group IC + E patients were treated with chemotherapy plus Endostatin injected arterially and intravenously and subsequent radiotherapy Group IC + E showed a progressionfree survival PFS of 12 months as compared to 7 months of group C a significant increase indeed p = 0037 Likewise the overall survival time higher in Group IC + E and Group IC was compared to Group C p = 0001 p = 0004 respectively The adverse or toxic side effects exhibited by Group IC + E were not significantly different from either Group IC or Group C Endostatin administered in combination with chemotherapeutic agents via both intravenous injection and arterial infusion enhanced the PFS and OS in advanced NSCLC without increasing the risk of toxicity
Keywords: